Syros Pharmaceuticals (SYRS) to Release Earnings on Tuesday

Syros Pharmaceuticals (NASDAQ:SYRS) is scheduled to be issuing its quarterly earnings data before the market opens on Tuesday, May 14th. Analysts expect the company to announce earnings of ($0.89) per share for the quarter.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings results on Wednesday, March 27th. The company reported ($1.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.04. The business had revenue of $0.39 million for the quarter, compared to the consensus estimate of $2.40 million. Syros Pharmaceuticals had a negative net margin of 1,656.34% and a negative return on equity of 227.91%. On average, analysts expect Syros Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Syros Pharmaceuticals Stock Up 1.4 %

Shares of NASDAQ SYRS opened at $5.15 on Wednesday. Syros Pharmaceuticals has a 52-week low of $2.09 and a 52-week high of $8.17. The company has a debt-to-equity ratio of 2.07, a quick ratio of 3.95 and a current ratio of 3.95. The stock has a market cap of $137.66 million, a P/E ratio of -0.89 and a beta of 1.75. The firm has a 50 day moving average price of $5.76 and a 200 day moving average price of $5.45.

Analyst Ratings Changes

SYRS has been the subject of several research analyst reports. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Syros Pharmaceuticals in a report on Monday, April 1st. Piper Sandler reiterated an “overweight” rating and set a $13.00 target price on shares of Syros Pharmaceuticals in a report on Wednesday, April 3rd. Finally, StockNews.com lowered Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, April 17th.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.